Location of Repository

The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines

By J.F Featherstone, A.G Speers, B.A Lwaleed, C.M Hayes, A.J Cooper and B.R Birch

Abstract

Objevtive: to assess whether microinjecting epirubicin into cells showing multidrug resistance (MDR, common to many cancers, including bladder cancer, with resistance to, e.g. anthracyclines and mitomycin C) spares the nucleus, as when these drugs accumulate, distribution in MDR cells characteristically spares the nucleus, suggesting that the nuclear membrane is responsible for excluding cytotoxic drugs from MDR nuclei.<br/><br/>Materials and methods: nuclear exclusion of drugs is an important feature of resistance in MDR cells, as many MDR-susceptible drugs have cytotoxic actions within the nucleus. Drug accumulation in 'classical' P-glycoprotein-mediated MDR cells is greatly reduced by efflux. Microinjection of epirubicin into the cytoplasm of MDR cells bypasses the P-glycoprotein efflux pump on the plasma membrane. Nuclear sparing would directly implicate the nuclear membrane in this phenomenon. Because of their fluorescence properties, which allow study by confocal microscopy and flow cytometry, anthracyclines have also been used extensively to investigate MDR. Thus sensitive (MGH-U1 and RT112) and MDR (MGH-U1R and MGH-U1-MMC) bladder cancer cell lines were used. Adherent cells from each cell line were individually microinjected with epirubicin (0.5 mg/mL) and a 77 kDa fluorescein isothiocyanate (FITC)-dextran (0.5 mg/mL). The pattern of nuclear epirubicin uptake in injected cells was then evaluated by confocal microscopy. The 77 kDa FITC-dextran allowed easier identification of injected cells and was also excluded from their nuclei.<br/><br/>Results: sensitive bladder cancer cell lines all showed a nuclear accumulation pattern of epirubicin, consistent with their normal uptake after exposure to epirubicin. The MDR cell lines showed the characteristic nuclear-sparing pattern of epirubicin uptake, similar to the normal uptake pattern after epirubicin exposure. The 77 kDa FITC-dextran showed clearly which cells had been microinjected, and was excluded from the nuclei of all injected cells. Cell viability was confirmed by acridine-orange staining after initial visualization of injected cells.<br/><br/>Conclusion: the nuclear membrane is responsible for the nuclear exclusion of epirubicin in MDR cells. Further work is necessary to determine the mechanisms involved

Topics: RT
Year: 2005
OAI identifier: oai:eprints.soton.ac.uk:19199
Provided by: e-Prints Soton

Suggested articles

Preview

Citations

  1. (2004). 153–7 Richie JP. Intravesical chemotherapy. Treatment selection, techniques and results.
  2. (2000). 32: 599–606 26 Bobichon
  3. (1992). 521– Tolley DA, Parmar MKB, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with seven years of follow-up.
  4. (1981). 585–7 Oosterlinck
  5. (1993). 749–52
  6. (1996). 819–23
  7. (1996). 824–9
  8. (2002). Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukaemia.
  9. (1996). Clinical significance of multi-drug resistance associated protein and Pglycoprotein in patients with bladder cancer.
  10. (1993). Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study.
  11. (1993). Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model.
  12. (1991). Examination by confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parents and multidrug resistant cell lines.
  13. (1994). High level expression of the MDR-1 gene in the normal bladder urothelium: a potential involvement in protection against carcinogens. Carcinogenesis
  14. (1997). Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin.
  15. (2001). MDR-1 P-glycoprotein reduces influx of substrates without affecting membrane potential.
  16. (1999). Multidrug resistance evaluation by confocal microscopy in primary urothelial cancer explant colonies. Cytotechnology
  17. (1979). Patterns of anthracycline retention modulation in human tumour cells. Cytometry
  18. (1995). The drug resistance-related protein LRP is the major vault protein. Nature Med 1995; 1: 578–82 29 Kiyomiya
  19. Ther Oncol 1996; 1: 49–61 27 Pante N, Aebi U. Toward a molecular understanding of the structure and function of the nuclear pore complex.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.